Muscle-Preserving Drugs and GLP-1 Weight Loss: Promise, Limits, and What Works Now
A clear-eyed look at the investigational drugs designed to protect lean mass during GLP-1 weight loss, and why protein and resistance training remain the proven strategy.
If you have started a GLP-1 medication, or you are weighing whether to, you have probably run into a worry that barely came up a few years ago: what happens to your muscle when the weight comes off fast? It is a fair question. And there is now a second layer to it, because a wave of experimental drugs is being tested specifically to protect muscle while you lose fat. You may have seen the headlines. Here is a plain, honest look at what that research actually shows, and what it does not, so you can tell the science from the hype.
Why muscle even enters the weight-loss conversation
When you drop a large amount of weight, you do not lose pure fat. Some of what leaves the scale is lean body mass, which includes muscle. That is true of dieting, of surgery, and of the newer medications. GLP-1 and combined GLP-1/GIP receptor agonists can drive substantial weight loss, in some studies up to about 25 percent of body weight, and reviews estimate that lean mass can account for roughly 15 to 40 percent of the total weight lost. That range is wide because people are different. The share depends on your age, your starting fitness, how much protein you eat, and how active you stay.
Losing some lean mass is not automatically a disaster, and it is worth saying that plainly. Context and function matter more than any single scan. Still, muscle does real work for you: strength, balance, blood-sugar handling, and metabolic rate all lean on it. If you want the longer version of why that matters, we cover it in why muscle matters for metabolism and in GLP-1 and muscle loss. The short version is that protecting muscle is worth caring about, and more so as you age.
What a muscle-preserving drug is trying to do
Your body has a built-in braking system on muscle growth. Proteins called myostatin and activin A act like a thermostat that keeps muscle from expanding without limit. They send their signal through docking points on muscle cells known as the activin type II receptors, or ActRIIA and ActRIIB. The investigational muscle-preserving agents all work somewhere along that pathway. Some block the receptor. Some mop up myostatin or activin before it can bind. The goal is the same: ease off the brake so that, while a GLP-1 strips away fat, your muscle is defended rather than surrendered.
Ready to start?
$199 Skeptics' Trial, see if it works for you
One month of medical-grade compounded semaglutide, the $119 doctor review, and a free B-12/lipotropic injection. No long-term commitment.
Start the 30-day trialOne point matters before we go further. Every drug named below is investigational. None is FDA-approved for preserving muscle or lean mass during weight loss. They have been studied mostly in Phase 2 and Phase 2b trials, over windows of about 16 to 72 weeks, using DXA scans to measure body composition. That is early-stage science, not something a clinic can prescribe for this purpose today.
Bimagrumab and the BELIEVE trial
Bimagrumab is a human monoclonal antibody that blocks those activin type II receptors. What makes it interesting is that, on its own, it has been shown to build muscle and reduce fat without suppressing appetite, which is a very different mechanism from a GLP-1. It is owned by Eli Lilly, which acquired the developer Versanis Bio in 2023, and it remains investigational.
In the Phase 2 BELIEVE trial, 507 adults with obesity were spread across nine treatment arms. The combination of high-dose bimagrumab plus semaglutide produced about 22 percent weight loss over 72 weeks, compared with about 15.7 percent for semaglutide alone and about 10.8 percent for bimagrumab alone. The body-composition story is the real headline. Semaglutide alone reduced lean mass by about 7.4 percent. Bimagrumab alone actually raised lean mass by about 2.5 percent. The combination held lean-mass loss to about 2.9 percent, and roughly 92 percent of the weight lost on the combination came from fat. Those figures describe what happened in one trial. They are not a promise, and results vary by individual.
Antibodies that target myostatin directly
A related approach uses antibodies that grab myostatin or activin A before they reach the receptor. In Regeneron's Phase 2 COURAGE trial, semaglutide was paired with trevogrumab, an anti-myostatin antibody, with or without garetosmab, an anti-activin A antibody. Adding trevogrumab preserved roughly 50 to 80 percent of the lean mass that would otherwise be lost with semaglutide alone, and the three-drug combination preserved about 81 percent. Both of those extra agents are investigational.
Scholar Rock's apitegromab, an antibody that binds the inactive precursor form of myostatin, was tested in the Phase 2 EMBRAZE trial in about 100 adults, added to tirzepatide. It showed a statistically significant preservation of lean mass, holding on to about 55 percent of the lean mass otherwise lost, with fat making up about 85 percent of the weight lost versus about 70 percent in the comparison group. Apitegromab is furthest along as a treatment for spinal muscular atrophy, a separate disease, where it has been under FDA review; for muscle preservation in obesity it remains investigational.
SARMs, and why the caution flag stays up
A different chemical class, selective androgen receptor modulators, or SARMs, has also entered this space. Veru's enobosarm is an oral SARM tested in the Phase 2b QUALITY study in 168 adults over age 60 who were on semaglutide. It reduced lean-mass loss by about 71 percent versus placebo at 16 weeks, and in the higher-dose group about 99 percent of the weight lost came from fat.
SARMs deserve an extra word of caution. No SARM is FDA-approved for any indication, and the class has drawn safety and regulatory scrutiny, including with unregulated products sold online. Enobosarm studied in a supervised trial is not the same thing as a SARM bought from a website, and neither is something to experiment with on your own.
The honest limits of these early results
The numbers above are genuinely encouraging, and that is exactly why they need a clear frame. A few things are worth holding in mind at the same time:
- Preserving lean mass on a DXA scan is not the same as proven gains in strength, physical function, or long-term health. These trials measured body composition over short windows, not years of outcomes.
- The trial percentages are averages across a group. Your own result could land better or worse, and results vary by individual.
- Safety is not settled. In the three-drug COURAGE arm there were substantially more dropouts for tolerability, and two deaths occurred, one from an undetermined cause and one from cardiac arrest. Regeneron reported that it had not identified a causal association with the treatment. Those events belong in an honest picture, and they underline that these combinations are still experimental.
- None of these agents is approved or available for muscle preservation. Right now they live inside clinical trials.
What is actually proven, and available, today
Here is the reassuring part. You do not have to wait for a pipeline to protect your muscle. The strategy with the strongest evidence is also the plainest: eat enough high-quality protein, and do regular resistance training. Protein rich in essential amino acids such as leucine, spread across your meals rather than crammed into one, gives muscle the raw material it needs. Resistance training, meaning working your muscles against real resistance a few times a week, gives them a reason to stay. Together they consistently blunt the lean-mass loss that can come with a GLP-1.
This matters most for older adults and for anyone already carrying low muscle relative to fat, a pattern we describe in sarcopenic obesity. If you are unsure where to begin on the training side, strength-training basics for weight loss walks through it without needing a gym full of equipment. The right amount of protein and the right kind of movement look a little different for each person, which is why an individualized plan beats a generic rule.
A quick note on names. Semaglutide is the active ingredient in medicines marketed as Ozempic and Wegovy by Novo Nordisk, and tirzepatide is the active ingredient in Mounjaro and Zepbound by Eli Lilly; those are trademarks of their respective makers, and this clinic is not affiliated with or endorsed by any of them. Where a compounded version of semaglutide or tirzepatide is used, keep in mind that compounded medications are not FDA-approved and not brand-identical, and results vary by individual.
The muscle-preserving drug pipeline is one of the more hopeful stories in metabolic medicine right now, and it is worth watching. But watching is the operative word. These are Phase 2 research programs, not prescriptions, and their long-term safety and real-world benefit are still unproven. If you are on a GLP-1 today, or considering one, the muscle question already has a good answer you can act on this week: enough protein, and consistent strength work, guided by someone who knows your health. The future may add new tools. The foundation is here now.
Frequently asked questions
Is there a pill or shot I can take to keep my muscle while on a GLP-1?
Not yet, honestly. The muscle-preserving agents in the news, such as bimagrumab, trevogrumab, apitegromab, and enobosarm, are all investigational and not FDA-approved for this use. They exist inside clinical trials, not on a prescription pad. Today the proven way to protect muscle is adequate high-quality protein plus regular resistance training, ideally as part of an individualized plan that fits your health.
How is bimagrumab different from Ozempic or Wegovy?
Semaglutide, the active ingredient in Ozempic and Wegovy from Novo Nordisk, works largely by reducing appetite. Bimagrumab, an investigational antibody owned by Eli Lilly, works on a muscle-growth pathway and does not suppress appetite; in trials it built muscle and reduced fat. Researchers are studying them together because the mechanisms differ. Bimagrumab is not approved for any use, and this clinic is not affiliated with either company.
Are SARMs like enobosarm safe to buy for muscle preservation?
No SARM is FDA-approved for any indication, and products sold online are unregulated and carry real safety concerns. Enobosarm has only been studied in supervised clinical trials. Please do not buy or use a SARM on your own, and never start, stop, or change any prescription without your prescriber, whose job it is to make that call with you.
Should I be worried about losing muscle on a weight-loss medication?
It is worth paying attention to, but not panicking over. Some lean-mass loss is normal with any large weight loss, and losing some is not automatically harmful; function and context matter more than a single number. You can protect most of it with enough protein and regular strength training. If you are older or already low on muscle, it deserves closer attention and a tailored plan.
When will muscle-preserving drugs actually be available?
There is no set date. The current evidence comes from Phase 2 and Phase 2b trials, and these programs still need larger, longer studies to establish safety and real functional benefit before any approval could be considered. It is a promising area to watch, but not a treatment you can get today. Meanwhile, the proven approach of protein plus resistance training is already available to you.
This article is informational only and not medical advice. Speak with a licensed physician before starting or changing any GLP-1 therapy. Individual results vary. New Hope Weight Loss is a physician-supervised medical weight loss clinic in Costa Mesa, CA. Eligibility for treatment is determined during the medical consultation. Compounded semaglutide and compounded tirzepatide are not the same products as Wegovy®, Ozempic®, Mounjaro®, or Zepbound®.